SymbolBBLGW
NameBONE BIOLOGICS CORP
SectorHEALTH CARE
RegionNorth America
IndustryIndustrial Specialties
Address2 BURLINGTON WOODS DRIVE,STE. 100, BURLINGTON, Massachusetts, 01803, United States
Telephone+1 781 - 552-4452
Fax
Email
Websitehttps://www.bonebiologics.com
IncorporationUNDEFINED
Incorporated On
Employees
Fiscal Year
Public Since
ExchangesNASDAQ
Auditor
Audit StatusNOT PROVIDED
Reporting Status
CIK
Description

Bone Biologics Corp is a healthcare solutions provider based in the United States. As a biotechnology firm, it engages its efforts in developing therapeutics to aid bone regeneration. The companys portfolio comprises its lead product, NELL-1, which is a bone void filler. Bone Biologics technology has application in the surgical specialties of spinal, orthopedic, general orthopedic, plastic reconstruction, neurosurgery, interventional radiology, and sports medicine.

Additional info from NASDAQ:
Bone Biologics Corp is a healthcare solutions provider based in the United States. As a biotechnology firm, it engages its efforts in developing therapeutics to aid bone regeneration. The companys portfolio comprises its lead product, NELL-1, which is a bone void filler. Bone Biologics technology has application in the surgical specialties of spinal, orthopedic, general orthopedic, plastic reconstruction, neurosurgery, interventional radiology, and sports medicine.

2026-03-13 20:35

(99% Neutral) BONE BIOLOGICS CORP (BBLGW) Announces Business Combination

Read more
2026-03-13 17:31

New Form 424B5 - Bone Biologics Corp <b>Filed:</b> 2026-03-13 <b>AccNo:</b> 0001493152-26-010072 <b>Size:</b> 390 KB

Read more
2026-03-02 18:36

New Form 10-K - Bone Biologics Corp <b>Filed:</b> 2026-03-02 <b>AccNo:</b> 0001493152-26-008564 <b>Size:</b> 6 MB

Read more
2026-01-08 13:05

(85% Positive) BONE BIOLOGICS CORPORATION (BBLGW) Announces Enrollment Update for products Due to Patient Enrollment Issues, Regulatory Process, Manufacturing Considerations

Read more
2026-01-08 13:00

Bone Biologics Highlights 2025 Key Operational, Scientific, and Corporate Milestones and Provides 2026 Outlook

Read more
2025-11-07 22:25

New Form SCHEDULE 13G/A - Bone Biologics Corp Filed: 2025-11-07 AccNo: 0001213900-25-107707 Size: 13 KB

Read more
2025-09-26 21:01

New Form S-8 - Bone Biologics Corp Filed: 2025-09-26 AccNo: 0001493152-25-015761 Size: 280 KB

Read more
2025-09-04 11:06

New Form 8-K - Bone Biologics Corp Filed: 2025-09-04 AccNo: 0001493152-25-012604 Size: 294 KB Item 7.01: Regulation FD Disclosure Item 9.01: Financial Statements and Exhibits

Read more
2025-08-29 14:30

New Form S-3/A - Bone Biologics Corp Filed: 2025-08-29 AccNo: 0001493152-25-012463 Size: 126 KB

Read more
2025-07-03 21:26

New Form SCHEDULE 13G - Bone Biologics Corp Filed: 2025-07-03 AccNo: 0001213900-25-061574 Size: 22 KB

Read more
Product Name Type Development Stage Therapeutic Area Study Status Trial ID
NB1 DEVICE Approved Degenerative Disc Disease RECRUITING NCT03810573
Total products: 1